Souhaitez-vous accéder aux communiqués récents ?

FDA Pre-New Drug Application (NDA) meeting granted for QTORIN™ rapamycin for the treatment of microcystic lymphatic malformations, with meeting expected in second quarter of 2026; NDA submission on...

Phase 2a follow-up period data for RAP-219 in focal onset seizures (FOS) demonstrated sustained seizure reduction, including a 90% median reduction in clinical seizures over baseline in weeks 9-12  ...

Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update

SANTA MONICA, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- The Macerich Company (NYSE: MAC) (the “Company” or “Macerich”), a leading owner, operator and developer of major retail properties in top...

Arcutis today reported financial results for the quarter ended March 31, 2026, and provided a business update.

Sydney, Australia, May 06, 2026 (GLOBE NEWSWIRE) -- Australian film director Flaminia Romani has entered a new phase of professional growth following her recent association with Phoenix...

Wrap Technologies, Inc. to Report First Quarter 2026 Financial Results on Wednesday, May 13, 2026 at 4:30 p.m. ET

Firm Founded in 2007 Now Ranks Among Top Five Black Law Firms in the Nation, Serving Clients Across Five Southern California Counties.

Early GO decision reached in CAPTIVATE in March 2026 based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A  Claseprubart granted...

Successfully met primary endpoint of HiSCR75 for both doses studied, demonstrating response rates of 42.2% for 150 mg dose (p=0.018) and 42.9% for 300 mg dose (p=0.015) at Week 16, which are the...